In Segment C, members will get ABBV-744 and oral navitoclax. In Phase D, members will acquire ABBV-744 and ruxolitinib. Contributors will get treatment right up until sickness progression or the contributors are unable to tolerate the study drugs. There may be increased treatment stress for members in this trial in https://stephenz211kvf3.yomoblog.com/profile